NCT07111013View on ClinicalTrials.gov

A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Dry Eye Disease

Interventions

DRUG

Lifitegrast/perfluorohexyloctane (PFHO)

fixed-dose combination (FDC) (5%/95%)

All Listed Sponsors

lead

Bausch & Lomb Incorporated

INDUSTRY